Intention‐to‐treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world-Reference-Cited by-同舟云学术

Intention‐to‐treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world

Published:2019-08-09 Issue:12 Volume:49 Page:1365-1373
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Tamori Akihiro¹^ORCID,Inoue Kazuaki²,Kagawa Tatehiro³,Takaguchi Koichi⁴,Nouso Kazuhiro⁵,Iwasaki Yoshiaki⁶,Minami Masahito⁷,Hai Hoang¹,Enomoto Masaru¹,Kawada Norifumi¹

Affiliation:

1. Department of HepatologyOsaka City University Graduate School of Medicine Osaka Japan

2. Department of GastroenterologyShowa University Yokohama Japan

3. Department of GastroenterologyTokai University Isehara Japan

4. Department of GastroenterologyKagawa Prefectural Central Hospital Takamatsu Japan

5. Department of GastroenterologyOkayama City General Medical Center Okayama Japan

6. Department of GastroenterologyOkayama University Okayama Japan

7. Aiseikai Yamashina Hospital Kyoto Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13410

Reference32 articles.

1. WHO.Hepatitis C. 18 July 2018. Available at:https://www.who.int/mediacenter/factsheets/fs164/en/. Accessed April 15 2019.

2. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

3. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

4. AASLD and IDSA.HCV guidance: Recommendations for testing managing and treating hepatitis C. Available at:http://www.hcvguidelines.org/. Accessed April 15 2019.

5. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study;JGH Open;2024-04

2. Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease;Gut and Liver;2023-10-16

3. Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid;Viruses;2023-02-09

4. Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study;Internal Medicine;2022-10-15

5. Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed;Internal Medicine;2021-11-01